Abstract The current study was designed to determine the beneficial effects of zinc supplementation on expressed levels of peroxisome proliferator-activated receptor gamma (PPAR-γ) and glucose transporter type 1 (GLUT1) genes in newborns of women with gestational diabetes mellitus (GDM). This randomized, double-blind, placebo-controlled clinical trial was performed among 40 women with GDM. Patients were randomly allocated to intake either 233 mg zinc gluconate (containing 30 mg zinc) (n = 20) or a placebo (n = 20) for 6 weeks.
Introduction
Gestational diabetes mellitus (GDM) is defined as insulin resistance or carbohydrate intolerance causing hyperglycemia with onset or first recognition at any time during pregnancy [1] . GDM associated with several maternal complications including preeclampsia, still birth, and requiring operative vaginal delivery or cesarean section, as well as several fetal complications such as prematurity, neonatal hypoglycemia, respiratory distress syndrome and hyperbilirubinemia [2] . In addition, hyperglycemia and altered concentration of fatty acid derivates may result in decreased expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) in the syncytiotrophoblast and the extravillous trophoblast of GDM placentas [3] . Previous studies have shown that PPAR-γ modulates the expression of several adipocyte-specific genes involved in lipid synthesis and storage, insulin signaling, and adipokine production [4, 5] .
In addition to zinc antioxidant and anti-inflammatory properties, previous studies reported that zinc appears to be essential for the protective properties of PPAR-α and PPAR-γ in vascular endothelial cells [6, 7] . In a study by Zhang et al. [8] , it was observed that high levels of Zn supplementation in weaned piglets increased the mRNA expression levels of PPAR-γ. In another study, it was reported that zinc deficiency markedly suppressed the mRNA expression of PPAR-γ [9] . In addition, placental glucose transporter type 1 (GLUT-1) plays an important function in transporting glucose from mother to fetus [10] . In a study by Ueda et al. [11] was seen that expression levels of placental GLUT-1 mRNA in zinc-deficient pregnant mice was significantly decreased than that observed in control pregnant mice, whereas it unchanged in zincsupplemented pregnant mice.
The DNA-binding domains of PPARs consist of two sets of zinc fingers [12] . The specificity and polarity of PPAR-DNA binding seem to be due at least in part to features in the zinc finger domains of PPARs [13] . We are aware of no randomized controlled trial that evaluated the effects of zinc supplementation on expressed levels of PPAR-γ and GLUT-1 genes in newborns of women with GDM. We hypothesized that zinc supplementation might affect expressed levels of PPAR-γ and GLUT-1 genes in newborns of women with GDM. Therefore, the present study was conducted to evaluate the beneficial effects of zinc supplementation on expressed levels of PPAR-γ and GLUT-1 genes in newborns of women with GDM.
Subjects and Methods

Trial Design
This was a 6-week randomized, double-blind, placebocontrolled clinical trial.
Participants
Participants were eligible for inclusion if they were 18-40 years of age with GDM diagnosed according to the American Diabetes Association criteria referred to the Naghavi Clinic in Kashan, Iran, between December 2015 and April 2016. In the current study, women with GDM diagnosed by Bone-step^2-h 75-g oral glucose tolerance test (OGTT) at 24-28-week gestation and singleton pregnancy were included. Diagnosis of GDM was as follows: pregnant women who met one of the following criteria were considered as having GDM: fasting ≥92 mg/dL, 1-h ≥180 mg/dL, and 2-h ≥153 mg/dL [14] . Women pregnant with preexisting diabetes, psychiatric disease, kidney or liver diseases, chronic hypertension, hypothyroidism, or smokers were excluded.
Ethics Statements
The present trial was conducted in accordance with the Declaration of Helsinki, and informed consent was received from all participants. The research was approved by the ethics committee of Kashan University of Medical Sciences (KUMS) and was registered in the Iranian website for registration of clinical trials (http://www.irct.ir: IRCT201503055623N42).
Study Design
At the onset of the study, patients were first matched one-byone according to preintervention BMI (<25 and ≥25 kg/m 2 ) and weeks of gestation (<26 or ≥26 weeks). Participants were then randomly divided into two groups to receive either zinc supplements (n = 20) or placebo (n = 20) for 6 weeks. Although the duration of intervention was 6 weeks, all participants were followed up until the delivery. Participants were requested not to change their ordinary physical activity and not to take any nutritional supplements during the 6-week trial. All patients completed 3-day food records and three physical activity records at the study baseline and weeks 2, 4, and 6 of the intervention. Daily macro-and micro-nutrient intakes were analyzed by nutritionist IV software (First Databank, San Bruno, CA). In the current study, physical activity was described as metabolic equivalents (METs) in hours per day. To determine the METs for each patient, we multiplied the times (in hour per day) reported for each physical activity by its related METs coefficient by standard tables [15] . Used tool to measure physical activity was questionnaire.
Intervention
In the intervention group, participants received 233 mg zinc gluconate (containing 30 mg zinc) supplements and group B received placebo. Due to the lack of evidence about the appropriate dosage of zinc for patients with GDM, we used 30 mg of zinc supplements based on a previous study during pregnancy [16] . Zinc supplements and its placebos (starch) were manufactured by Donyayeh Behesht Pharmaceutical Company (Tehran, Iran) and Barij Essence Pharmaceutical Company (Kashan, Iran), respectively. All zinc and placebo tablets were provided by Barij Essence Pharmaceutical Company in prepacked bottles numbered for each patient according to the randomization sequence.
Treatment Adherence
Every 2 weeks, subjects were taken enough supplements and placebos to last 3 days after their next scheduled visit and were instructed to return all unused supplements and placebos at each visit. The remaining supplements and placebos were counted and subtracted from the number provided to determine the number taken. To increase the compliance, all participants were receiving short messages on their cell phones to take supplements and placebos every day.
Assessment of Anthropometric Variables
A trained midwife at the maternity clinic did anthropometric measurements at the onset of the study and end-of-trial. Body weight and height (Seca, Hamburg, Germany) were determined while patients were minimally clothed and no shoes. Then, BMI [weight (kg) / height 2 (m)] was calculated. All anthropometric measures were done by a trained midwife.
Outcomes
In the present study, the primary outcome was PPAR-γ and the secondary study outcome was GLUT1.
Isolation of Lymphocyte Cells
At first, 10 ml blood samples were obtained from umbilical cord blood of newborns of women with GDM at delivery time. Then, lymphocyte cells were extracted from umbilical cord blood of newborns of women with GDM using a 50 % Percoll (Sigma-Aldrich, Dorset, UK) gradient. Thus, for preparing a stock isotonic Percoll solution, osmolity of the solution was adjusted by adding one part of 10× concentrated cell culture medium into the nine parts of Percoll. Osmolality of the stock solution was checked by osmometer model 3300 (LabX, EI Cajon, USA). Solution of stock isotonic Percoll (SIP) was diluted by adding normal cell culture medium. The cells of lymphocytes which were at the interface of Percoll and serum were removed by using a Pasteur pipette and washed a few times with phosphate-buffered saline (PBS). Samples were taken for cell count and viability testing by trypan blue, RNA and DNA extraction.
Total RNA Extraction
In order to RNA extraction, the RNXplus kit (Cinnacolon, Tehran, Iran) was used. Total RNA extraction from all prepared samples was done as recommended protocol by manufacture. After preparation of homogenate, the cells powder was harvested and resuspended in 1 ml of RNAXplus reagent in a clean RNase-free tube. After incubation for 5 min at room temperature, the sample was pipetted and subsequently treated with addition of 200 μl of chloroform. The mixture was incubated at room temperature for 5 min after shaking rigorously for 15 s. The mixture was centrifuged at 12,000g for 15 min, and the aqueous phase containing the RNA was transferred to a clean RNase-free tube. The total RNAwas precipitated at room temperature for 15 min. The pellet including total RNA was washed by using 75 % ethanol and centrifuged at 7500g for 8 min. After drying ethanol, the RNA pellet was resuspended in 50 μl or less of TE buffer. The concentration of total RNA was calculated based on OD 260/280 ration measurements as a means to means to address purity of RNA. To confirm the integrity of extracted RNA, it was electrophoresed. RNA suspension was frozen in −20°C until cDNA making. Following the extraction of the total RNAs from each sample, RNA quantification were performed by UV spectrophotometer. Each samples OD 260/280 ratio between 1.7 and 2.1 was intended that shows no contamination with both protein and DNA.
First Strand cDNA Synthesis Procedure
The first strand cDNA synthesis can be performed as an individual reaction or as a series of parallel reactions with different RNA templates. Therefore, the reaction mixture can be provided by merging reagents individually or a master mix can be prepared all of the components except template RNA. Depending on the structure of RNA templates, separate steps for RNA denaturation and primer annealing many improve RT-PCR results. The isolated RNA was reverse transcribed to cDNA library using Moloney murine leukemia virus (MMLV) reverse transcriptase (RT). Reverse transcription was performed with random primers.
Gene Expression
Expressed levels of PPAR-γ and Glut-1 were evaluated by quantitative RT-PCR, using the LightCycler technology (Roche Diagnostics, Rotkreuz, Switzerland) with SYBR g r e e n d e t e c t i o n a n d A m p l i c o n K i t ( Ta b l e 1 ) . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used as a loading control (forward A A G C T C AT T T C C T G G TAT G A C A A C G ; r e v e r s e TCTTCCTCTTGTGCTCTTGCTGG). As template, approximately 50 ng cDNA was applied in a quantitative real-time RT-PCR, and the signals were detected using a real-time PCR system. All reactions were run in duplicates. All primers were designed using Primer Express Software (Applied Biosystems) and Beacon designer software then, purchased from Takaposizt Company, Iran. Relative transcription levels were calculated using Pffafi method or 2 −ΔΔCT . Normalization of gene expression data is used to correct sample-to-sample variation. Starting material obtained from different individuals usually varies in tissue mass or cell number, RNA integrity or quantity, or experimental treatment. The ideal control gene should be expressed in an unchanging fashion regardless of experimental conditions, including different tissue or cell types, developmental stage, or sample treatment. Because there is no one gene that meets this criterion for every experimental condition, it is necessary to validate the expression stability of a control gene for the specific requirements of an experiment prior to its use for normalization. Also, GAPDH gene (housekeeping gene) was used for normalization.
Assessment of Zinc Levels
A serum zinc concentration at the study baseline and 6 weeks after intervention among GDM women was evaluated using zinc kit (Elitech, Puteaux, France).
Randomization
Randomization assignment was done using computergenerated random numbers. Randomization and allocation were concealed from the researchers and participants until the final analyses were completed. The randomized allocation sequence, enrolling participants and allocating them to interventions were conducted by a trained staff at the clinic.
Statistical Analysis
We applied the Kolmogrov-Smirnov test to examine if variables were normally distributed. Independent samples Student's t test was used to detect differences in general characteristics and macro-and micro-nutrients dietary intakes between the two groups. To determine the effects of zinc supplementation on PPAR-γ and GLUT1 mRNA levels, we used independent samples Student's t test. All statistical analyses were done using the Statistical Package for Social Science version 17 (SPSS Inc., Chicago, IL, USA).
Results
At the study baseline, we recruited 50 patients; however, 10 subjects were excluded from the study because of not meeting inclusion criteria (n = 6) and needed to start insulin therapy (n = 4). In the current study, 40 participants [zinc (n = 20) and placebo (n = 20)] completed the trial (Fig. 1) . On average, the rate of compliance in the present study was high, such that 100 % of zinc supplements were taken throughout the study in both groups. No side effects were reported following the consumption of zinc supplements in women with GDM throughout the study.
No significant difference existed in the anthropometric measures before and after the intervention between the two groups (data not shown).
Comparison of total calorie intake, macro-and micronutrients between the two groups based on the 3-day dietary records throughout the study no statistically significant difference was shown (data not shown).
After 6 weeks of intervention, the change in serum zinc levels was greater in women consuming zinc than in the placebo group (+11.1 ± 13.4 vs. −4.8 ± 17.3 mg/dL, P = 0.002). Quantitative results of RT-PCR demonstrated that compared with the placebo, zinc supplementation resulted in a significant increase of expressed levels of PPAR-γ mRNA (P < 0.001) in umbilical cord blood of newborns of women with GDM (Fig. 2) .
A significant increase in expressed levels of GLUT1 mRNA (P < 0.001) in umbilical cord blood of newborns of women with GDM following the supplementation of zinc compared with the placebo among GDM women (Fig. 3) .
Discussion
This study assessed the beneficial effects of zinc supplementation on expressed levels of PPAR-γ and GLUT1 genes in newborns of women with GDM. The current study shown that zinc supplementation for 6 weeks among GDM women increased the mRNA levels of PPAR-γ and GLUT1 in their newborns compared with the placebo group. To our knowledge, the current study is the first that reports the beneficial effects of zinc supplementation on expressed levels of PPAR-γ and GLUT1 genes in newborns of women with GDM.
Pregnant and GDM women are sensitive to micronutrient deficiency, inflammation, and various fetal and maternal aberrations [17, 18] . Our study demonstrated that zinc supplementation for 6 weeks among GDM women increased the mRNA levels of PPAR-γ in their newborns compared with the placebo group. In line with our findings, in a study by Zhang et al. [8] , it was observed that the mRNA levels of PPAR-γ were significantly higher in all zinc treatments (250, 380, 570, and 760 mg zinc/kg of the basal diet) in weaned piglets. In addition, zinc supplementation increased PPAR-γ expression and activation as well as downregulated interleukin (IL)-6 expression and production in porcine endothelial cells [9] . Previous studies have shown that zinc deficiency induces PPAR-γ signaling, pro-inflammatory phenotype and atherosclerosis in vascular endothelial cells and LDL-receptor knockout mice [7, 19] . However, no significant difference was observed for PPAR-γ activity after low-zinc intake (0.5-1.5 mg/kg) in mice fed with a high-fat diet [20] . PPAR-γ is a member of the nuclear receptor superfamily and regulates the expression of several genes encoding proteins involved in adipocyte differentiation, fatty acid storage and glucose metabolism [21] . Downregulation PPAR-γ plays an important role in the pathology of numerous diseases such as diabetes, atherosclerosis, and cancer [22] . The mechanisms and regulation of PPAR-γ signaling by zinc remain mostly unknown. The current study clearly showed that zinc is critical for normal and constitutive PPAR-γ activity and that zinc deficiency can lead to dysfunction of PPAR-γ signaling. Previous reports have demonstrated that zinc may be required for the expression of PPAR-γ as a zinc finger protein [23, 24] because the DNA-binding domain of PPAR-γ contains a zinc finger motif, which plays an important role in the specificity and polarity of PPAR receptor DNA binding. Furthermore, the direct involvement of zinc as a functional component of zinc fingers in the regulation of PPAR-γ was supported by Meerarani et al. [9] study, which clearly indicated that the PPAR-γ agonist-mediated downregulation of the transcription factor NF-kB was impaired during zinc deficiency.
The current study revealed that zinc administration for 6 weeks among GDM women increased the mRNA levels of GLUT1 in their newborns compared with the placebo group. In a study by Ueda et al. [11] , it was seen that at day 17 of gestation, the expression of placental GLUT1 mRNA did not affect following the supplementation with zinc, but that observed in zinc-deficient mice significantly decreased to 70 % of that observed in control mice. However, zinc element did not influence expressed levels of GLUT1 in C6 rat glioma and GP8 rat brain endothelial cells [25] . Some studies have demonstrated that neonates who had mothers with PGDM had higher rates of neonatal hypoglycemia [26, 27] . Placental GLUT1 plays a key role in transporting glucose from mother to fetus [10] . Therefore, supplying glucose for use as a placental and fetal fuel may be decreased in zincdeficient pregnant women. In a study by Wang et al. [28] , it was demonstrated that zinc levels in serum of women with GDM compared with normal pregnant women had a decreasing trend. However, the regulation of placental GLUT1 expression remains unclear [29] . In accordance with the importance of zinc for fetal development, zinc deficiency during pregnancy has reported that is associated with congenital malformations and embryonic and fetal deaths [30] . Strengths of the current study were the blinding of participants and without dropout rate. The current study has some limitations. First of the all, the duration of this study was low. We did not continue zinc supplementation up to delivery time. Future studies with longer duration of the intervention and bigger sample size are needed to confirm the validity of our findings. Second, we did not evaluate the effects of zinc supplementation on other expressed levels including markers related with inflammatory factors and biomarkers of oxidative stress.
Conclusions
Taken together, the current study demonstrated that zinc supplementation for 6 weeks among GDM women increased the mRNA levels of PPAR-γ and GLUT1 in their newborns compared with the placebo group. Findings of the current study suggest that zinc supplementation may confer advantageous therapeutic potential for patients with GDM.
